Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer

被引：6

作者：

Kodama, Hirotake ^{[1
]}

Hatakeyama, Shingo ^{[1
]}

Narita, Shintaro ^{[2
]}

Takahashi, Masahiro ^{[3
]}

Sakurai, Toshihiko ^{[4
]}

Kawamura, Sadafumi ^{[5
]}

Hoshi, Senji ^{[6
]}

Ishida, Masanori ^{[7
]}

Kawaguchi, Toshiaki ^{[8
]}

Ishidoya, Shigeto ^{[9
]}

Shimoda, Jiro ^{[7
]}

Narita, Takuma ^{[1
]}

Sato, Hiromi ^{[2
]}

Mitsuzuka, Koji ^{[3
]}

Tochigi, Tatsuo ^{[5
]}

Tsuchiya, Norihiko ^{[4
]}

Arai, Yoichi ^{[5
]}

Habuchi, Tomonori ^{[2
]}

Ohyama, Chikara ^{[1
]}

机构：

[1] Hirosaki Univ, Dept Urol, Sch Med, Hirosaki, Aomori, Japan

[2] Akita Univ, Dept Urol, Sch Med, Akita, Japan

[3] Tohoku Univ, Dept Urol, Sch Med, Aoba Ku, Sendai, Miyagi, Japan

[4] Yamagata Univ, Dept Urol, Sch Med, Yamagata, Japan

[5] Miyagi Canc Ctr, Dept Urol, Natori, Miyagi, Japan

[6] Yamagata Prefectural Cent Hosp, Dept Urol, Yamagata, Japan

[7] Iwate Prefectural Isawa Hosp, Dept Urol, Mizusawa Ku, Oshu, Iwate, Japan

[8] Aomori Prefectural Cent Hosp, Dept Urol, Aomori, Japan

[9] Sendai City Hosp, Dept Urol, Taihaku Ku, Sendai, Miyagi, Japan

来源：

CLINICAL GENITOURINARY CANCER | 2019年 / 17卷 / 06期

基金：

日本学术振兴会;

关键词：

Castration-resistant prostate cancer; Prostate cancer; PSA; Sequential therapy; Survival; ANDROGEN DEPRIVATION; CHEMOTHERAPY; THERAPY;

D O I：

10.1016/j.clgc.2019.05.029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigate the effect of low prostate-specific antigen (PSA) on prognosis in 575 patients with metastatic castration-naive prostate cancer. The overall survival after castration-resistant prostate cancer diagnosis was significantly shorter in the PSA < 100 group than in the PSA >= 100 group. PSA < 100 ng/mL might be a poor prognostic factor in patients with metastatic castration-naive prostate cancer after castration-resistant prostate cancer. Introduction: This study aimed to investigate the effect of low prostate-specific antigen (PSA) on prognosis, as the association of initial PSA level with prognosis in patients with metastatic castration-naive prostate cancer (mCNPC) remains unclear. Patients and Methods: We evaluated 575 patients with mCNPC from 10 hospitals. Patients were stratified into 2 groups according to their initial PSA: PSA < 100 and PSA >= 100 groups. We compared castration-resistant prostate cancer (CRPC)-free survival, overall survival (OS), and OS from the CRPC diagnosis between the groups. Multivariate Cox regression analysis was performed to evaluate the effect of initial PSA level on prognosis. Results: Of the 575 patients, 196 (34%) patients belonged to the PSA < 100 group. No significant difference was found in patients' backgrounds except for PSA, the extent of disease, and high tumor burden between the groups. CRPC-free survival was significantly shorter in the PSA >= 100 group than in the PSA < 100 group. However, the OS after CRPC diagnosis was significantly shorter in the PSA < 100 group than that of the PSA >= 100 group. Multivariate analyses showed that PSA < 100 ng/mL was an independent factor for OS after CRPC, whereas no significant association was observed in the CRPC-free survival and OS. Conclusions: A significant effect of initial PSA < 100 ng/mL on OS after CRPC was observed. PSA < 100 ng/mL might be a poor prognostic factor in patients with mCNPC after CRPC.

引用

页码：E1091 / E1098

页数：8

共 50 条

[21] Prognostic Role of Prostate-specific Antigen Isoforms and Their Early Kinetics in Patients With Metastatic Castration-resistant Prostate Cancer Receiving New Generation Androgen Receptor Targeted Agents
Fiala, ONDrEJ
Hosek, Petr
Korunkova, Hana
Tkadlecova, Michaela
Hora, Milan
Sikova, Dominika
Stransky Jr, Petr
Finek, JINDrICH
Kucera, Radek
Windrichova, Jindra
Topolcan, ONDrEJ
IN VIVO, 2025, 39 (02): : 859 - 869
[22] Treatment Outcomes in Non-Metastatic Prostate Cancer Patients With Ultra-High Prostate-Specific Antigen
Tai, Patricia
Tonita, Jon
Woitas, Carla
Zhu, Tong
Joseph, Kurian
Skarsgard, David
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (04): : E525 - E530
[23] Clinical Outcomes of Chemotherapy Naive Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo
Taplin, Mary-Ellen
Armstrong, Andrew J.
Lin, Ping
Krivoshik, Andrew
De Phung
Parli, Teresa
Tombal, Bertrand
Beer, Tomasz M.
JOURNAL OF UROLOGY, 2017, 198 (06) : 1325 - 1333
[24] Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
Raju, Govinda Nanjaiah Laxmana
Bhat, Parineetha P.
Nagini, Siddavaram
JOURNAL OF LABORATORY PHYSICIANS, 2023, 15 (02) : 237 - 242
[25] Prostate-specific antigen kinetics in localized and advanced prostate cancer
Fitzpatrick, John M.
Banu, Eugeniu
Oudard, Stephane
BJU INTERNATIONAL, 2009, 103 (05) : 578 - 587
[26] Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer
McArdle, Peter A.
Mir, Khurram
Almushatat, A. S. K.
Wallace, A. Michael
Underwood, Mark A.
McMillan, Donald C.
UROLOGIA INTERNATIONALIS, 2006, 77 (02) : 127 - 129
[27] Racial differences in prostate-specific antigen levels and prostate-specific antigen densities in patients with prostate cancer
Abdalla, I
Ray, P
Ray, V
Vaida, F
Vijayakumar, S
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (06): : 537 - 541
[28] Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer
Turner, Jeffrey
Chaudhary, Uzair
ANTI-CANCER DRUGS, 2009, 20 (03) : 215 - 216
[29] Metastatic prostate cancer with normal level of serum prostate-specific antigen
R. Nishio
Y. Furuya
O. Nagakawa
H. Fuse
International Urology and Nephrology, 2003, 35 (2) : 189 - 192
[30] Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer
Weber, Manuel
Hadaschik, Boris
Ferdinandus, Justin
Rahbar, Kambiz
Beogemann, Martin
Herrmann, Ken
Fendler, Wolfgang P.
Kesch, Claudia
EUROPEAN UROLOGY FOCUS, 2021, 7 (02): : 279 - 287

← 1 2 3 4 5 →